AU2008276840B2 - Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound - Google Patents

Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound Download PDF

Info

Publication number
AU2008276840B2
AU2008276840B2 AU2008276840A AU2008276840A AU2008276840B2 AU 2008276840 B2 AU2008276840 B2 AU 2008276840B2 AU 2008276840 A AU2008276840 A AU 2008276840A AU 2008276840 A AU2008276840 A AU 2008276840A AU 2008276840 B2 AU2008276840 B2 AU 2008276840B2
Authority
AU
Australia
Prior art keywords
deoxy
composition according
fatty acid
compound
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008276840A
Other languages
English (en)
Other versions
AU2008276840A1 (en
Inventor
Yasuhiro Harada
Junichi Kawasaki
Yoshie Nishimura
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
R Tech Ueno Ltd
Original Assignee
Sucampo GmbH
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH, R Tech Ueno Ltd filed Critical Sucampo GmbH
Publication of AU2008276840A1 publication Critical patent/AU2008276840A1/en
Priority to AU2013203903A priority Critical patent/AU2013203903A1/en
Application granted granted Critical
Publication of AU2008276840B2 publication Critical patent/AU2008276840B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2008276840A 2007-07-19 2008-07-16 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound Ceased AU2008276840B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203903A AU2013203903A1 (en) 2007-07-19 2013-04-11 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92994807P 2007-07-19 2007-07-19
US60/929,948 2007-07-19
PCT/JP2008/063222 WO2009011449A2 (en) 2007-07-19 2008-07-16 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203903A Division AU2013203903A1 (en) 2007-07-19 2013-04-11 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Publications (2)

Publication Number Publication Date
AU2008276840A1 AU2008276840A1 (en) 2009-01-22
AU2008276840B2 true AU2008276840B2 (en) 2013-10-03

Family

ID=39720491

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008276840A Ceased AU2008276840B2 (en) 2007-07-19 2008-07-16 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Country Status (14)

Country Link
US (2) US8969324B2 (enrdf_load_stackoverflow)
EP (2) EP2327398A3 (enrdf_load_stackoverflow)
JP (2) JP5390519B2 (enrdf_load_stackoverflow)
KR (1) KR101485212B1 (enrdf_load_stackoverflow)
CN (2) CN103393618A (enrdf_load_stackoverflow)
AU (1) AU2008276840B2 (enrdf_load_stackoverflow)
BR (1) BRPI0814115B8 (enrdf_load_stackoverflow)
CA (1) CA2691995C (enrdf_load_stackoverflow)
IL (1) IL203064B (enrdf_load_stackoverflow)
MX (1) MX339727B (enrdf_load_stackoverflow)
NZ (2) NZ595270A (enrdf_load_stackoverflow)
RU (3) RU2506072C2 (enrdf_load_stackoverflow)
TW (2) TWI552772B (enrdf_load_stackoverflow)
WO (1) WO2009011449A2 (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2420291C3 (ru) 2006-01-24 2020-07-21 Р-Тек Уено, Лтд. Состав в мягкой желатиновой капсуле
SG10201606442QA (en) * 2011-08-05 2016-09-29 Sucampo Ag Method for treating schizophrenia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
JP6580414B2 (ja) * 2015-08-07 2019-09-25 小林製薬株式会社 生薬末含有錠剤
US10716544B2 (en) 2015-10-08 2020-07-21 Zmk Medical Technologies Inc. System for 3D multi-parametric ultrasound imaging
CN108619107A (zh) * 2018-05-28 2018-10-09 青海制药厂有限公司 一种含鲁比前列酮的软胶囊及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583174B1 (en) * 1999-10-15 2003-06-24 Sucampo, A.G. Composition and method for stabilizing the same
WO2006080549A2 (en) * 2005-01-27 2006-08-03 Sucampo Ag Method and composition for treating central nervous system disorders
WO2006093348A2 (en) * 2005-03-04 2006-09-08 Sucampo Ag Method and composition for treating peripheral vascular diseases
WO2007086536A2 (en) * 2006-01-24 2007-08-02 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE572839A (enrdf_load_stackoverflow) * 1958-02-12
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
US4301175A (en) * 1980-12-29 1981-11-17 The Upjohn Company E-Type prostaglandin compositions
US4431833A (en) * 1982-12-27 1984-02-14 American Cyanamid Company Prostaglandin and hydroxylated fatty acid ester formulations
KR920007569B1 (ko) * 1984-11-30 1992-09-07 쥬우가이 세이야꾸 가부시끼가이샤 프로스타글란딘 e 유도체의 안정한 제제의 제조방법
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US6183466B1 (en) * 1998-08-21 2001-02-06 Alza Corporation Dosage form comprising a capsule
DE60319355T3 (de) * 2002-04-25 2012-01-05 Banner Pharmacaps Inc. Kaubare weichkapsel
FR2850275B1 (fr) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
ATE402759T1 (de) * 2004-02-17 2008-08-15 Symrise Gmbh & Co Kg Überzogene, sphärische, nahtlose, gefüllte kapseln

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583174B1 (en) * 1999-10-15 2003-06-24 Sucampo, A.G. Composition and method for stabilizing the same
WO2006080549A2 (en) * 2005-01-27 2006-08-03 Sucampo Ag Method and composition for treating central nervous system disorders
US20060194880A1 (en) * 2005-01-27 2006-08-31 Sucampo Ag Method for treating central nervous system disorders
WO2006093348A2 (en) * 2005-03-04 2006-09-08 Sucampo Ag Method and composition for treating peripheral vascular diseases
WO2007086536A2 (en) * 2006-01-24 2007-08-02 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BECK, G. et al Prostaglandins, Vol. 20, No. 1, page 153169. 1 July 1980 *
LIPPMANN, w. et al EXPERIENTIA, BIRKHAEUSER VERLAG. Vol 29, No. 8, page 993995. 15 August 1973 *

Also Published As

Publication number Publication date
IL203064B (en) 2018-02-28
CN101808623B (zh) 2013-08-14
RU2013135403A (ru) 2015-02-10
RU2506072C2 (ru) 2014-02-10
JP2010533707A (ja) 2010-10-28
JP5390519B2 (ja) 2014-01-15
KR20100053563A (ko) 2010-05-20
KR101485212B1 (ko) 2015-01-22
EP2178516B1 (en) 2015-09-09
EP2327398A2 (en) 2011-06-01
EP2327398A3 (en) 2014-05-21
RU2010105847A (ru) 2011-08-27
WO2009011449A3 (en) 2010-04-29
CA2691995C (en) 2016-04-26
TWI552772B (zh) 2016-10-11
TW201436824A (zh) 2014-10-01
US20090022787A1 (en) 2009-01-22
TWI446912B (zh) 2014-08-01
EP2178516A2 (en) 2010-04-28
BRPI0814115A2 (pt) 2015-02-03
US9254326B2 (en) 2016-02-09
BRPI0814115B1 (pt) 2019-04-02
US20150126609A1 (en) 2015-05-07
NZ595270A (en) 2013-04-26
JP2014001247A (ja) 2014-01-09
RU2018113296A (ru) 2019-10-14
AU2008276840A1 (en) 2009-01-22
WO2009011449A2 (en) 2009-01-22
CA2691995A1 (en) 2009-01-22
RU2651471C2 (ru) 2018-04-19
MX339727B (es) 2016-06-06
BRPI0814115B8 (pt) 2021-05-25
MX2010000693A (es) 2010-06-01
CN101808623A (zh) 2010-08-18
US8969324B2 (en) 2015-03-03
TW200911273A (en) 2009-03-16
CN103393618A (zh) 2013-11-20
NZ583203A (en) 2011-10-28

Similar Documents

Publication Publication Date Title
AU2007208632B2 (en) Soft-gelatin capsule formulation
US9254326B2 (en) Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
US8669284B2 (en) Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
AU2013203903A1 (en) Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired